• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase m

tetano

Editor, Senior Moderator
J Virol. 2012 Jul 18. [Epub ahead of print]
Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.
Wong DD, Choy KT, Chan RW, Sia SF, Chiu HP, Cheung PP, Chan MC, Peiris JS, Yen HL.
Source

Centre of Influenza Research, LKS Faculty of Medicine, The University of Hong Kong.
Abstract

Limited antiviral compounds are available for the control of influenza and the emergence of resistant variants would further narrow the options for defense. The H275Y neuraminidase (NA) mutation that confers resistance to oseltamivir carboxylate has been identified among the seasonal H1N1 and 2009 pandemic influenza viruses; however, their H275Y resistant variants demonstrate distinct epidemiological outcome in humans. Specifically, dominance of the H275Y variant over the oseltamivir-sensitive viruses was only reported for a seasonal H1N1 variant during 2008-2009. Here, we systematically analyze the effect of the H275Y NA mutation on viral fitness and transmissibility of A(H1N1)pdm09 and seasonal H1N1 influenza viruses. The NA gene from A(H1N1)pdm09 A/California/04/09 (CA04), seasonal H1N1 A/New Caledonia/20/1999 (NewCal), and A/Brisbane/59/2007 (Brisbane) was individually introduced into the genetic background of CA04. The H275Y mutation led to reduced NA enzyme activity, increased K(M) for 3' -sialylactose or 6' -sialylactose, and decreased infectivity in mucin-secreting human airway epithelial cells when compared to the oseltamivir-sensitive wild-type counterparts. Attenuated pathogenicity in both RG-CA04(NA-H275Y) and RG-CA04?Brisbane(NA-H275Y) viruses was observed in ferrets when compared to RG-CA04 virus, although their transmissibility was minimally affected. In parallel experiments using recombinant Brisbane viruses differing by HA and NA, comparable direct-contact and respiratory-droplet transmissibility was observed among RG-NewCal(HA,NA), RG-NewCal(HA,NA-H275Y), RG-Brisbane(HA,NA-H275Y), and RG-NewCal(HA)?Brisbane(NA-H275Y) viruses. Our results demonstrate that despite the H275Y mutation led to a minor reduction in viral fitness, the transmission potential of three different antigenic strains carrying this mutation was comparable using the na?ve ferret model.

PMID:
22811535
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22811535
 
Back
Top Bottom